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Abstract: The purpose of this review is to present the most recent findings in bone tissue 
engineering. Special attention is given to multifunctional materials based on collagen and 
collagen–hydroxyapatite composites used for skin and bone cancer treatments. The multi­
functionality of these materials was obtained by adding to the base regenerative grafts proper 
components, such as ferrites (magnetite being the most important representative), cytostatics 
(cisplatin, carboplatin, vincristine, methotrexate, paclitaxel, doxorubicin), silver nanoparticles, 
antibiotics (anthracyclines, geldanamycin), and/or analgesics (ibuprofen, fentanyl). The suit­
ability of complex systems for the intended applications was systematically analyzed. The 
developmental possibilities of multifunctional materials with regenerative and curative roles 
(antitumoral as well as pain management) in the field of skin and bone cancer treatment are 
discussed. It is worth mentioning that better materials are likely to be developed by combining 
conventional and unconventional experimental strategies.
Keywords: bone graft, cancer, collagen, magnetite, cytostatics, silver
Introduction
Bone is one of the naturally occurring composite materials that still does not have an 
artificial correspondent.1 The interdependence between its morphology and properties 
is well understood, and two types of bone structures – cortical (compact) and trabecular 
(spongy) – can be easily identified. These different morphologies seem to be induced 
by piezoelectricity, with cortical bone being a result of a mechanically assisted bio­
mineralization process.2 The arrangement of osteons along with the loading direction 
can be explained by piezoelectricity. Recently, Noris­Suárez et al reproduced natural 
biomineralization conditions in vitro. They proved that the mechanical loading of the 
collagenous material induces important modifications upon the mineral­deposition 
process. They demonstrated that once mechanical loading takes place, the collagen 
fibers became arched and the negative charges appear especially distributed on the 
compressed zones. This is why mineralization occurs predominantly on the compressed 
areas, even if no osteoblasts are present.3
Tissue engineering is of interest for researchers especially because of the increas­
ing need for grafting materials.4 The starting monolithic materials have been continu­
ously improved by adding different components aimed at inducing new properties or 
to improve existing ones.5–9 The most common improvements have been related to the 
increase of healing rate, biocompatibility, or mechanical properties, or with the inducing 
of new properties, such as antimicrobial, anti­inflammatory, or analgesic activity. These 
new properties are sought after to avoid certain undesirable side effects or infections.7,9–11 
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The complex composition and morphology of bone tissues 
confers them remarkable properties and functionalities.1,12–14 
In the last few decades, many researchers have invested their 
efforts in developing new materials for bone grafting inspired 
in bone composition and structure.15 The compositions of 
bone and some of the most studied bone grafts are presented 
in Table 1. The systematic study of bone grafts can be con­
sidered to have started in the early twentieth century, when 
different transplants were done (allografts and xenografts).16 
Nowadays, special attention is paid to the synthesis of new 
bone grafts based on composite (nano)materials. Also, many 
papers deal with the important issue of how to design these 
materials in order to obtain improved biological properties. 
Biocompatibility and biointegration are usually realized by 
using engineered composite (nano)materials starting from 
natural polymers, calcium phosphates, and bone cells.5,6
Based on the classification made by Ashby et al,17 nowadays 
there is a gradual transition occurring from the “nano­ and 
bio­” age to a material­design age. During the nano­ and bio­
age, scientists focused their attention on improving material 
properties by decreasing materials’ size to the nanometric scale, 
but also paid attention to improving biological assessment in 
order to be better accepted by the human and animal body.18 
The material­design age maintains this principal concern, but 
improvements are achieved by optimizing such material char­
acteristics as porosity, hydrophilicity, pore size, distribution, 
and shape, etc.19,20 This is why there are a lot of papers dealing 
with material design or tissue­engineered nanobiomaterials, 
or even with both concepts.5,12,13,21–27 The use of bone cells for 
obtaining bone grafts could bring some major advantages: 
1) the cells could be gathered from the patient and cultured in 
vitro; 2) the opportunity for using available stem cells that can 
be differentiated under proper conditions into bone cells; and 
3) bone graft seeded with bone cells has the ability of being 
easily invaded by new bone ingrowth, thus promoting a much 
faster integration and the achievement of natural bone proper­
ties in a shorter time, in safe conditions, and with less donor 
tissue compared with classical auto­ and allografting proce­
dures.36,37 Moreover, the bone graft can act as a drug­delivery 
system for antibiotics and consequently enhance bone ingrowth 
in conjunction with wound healing.37
Worldwide, cancer remains the second­most common 
cause of death, despite the advances in prevention, early 
detection, and protocols of treatment. It is well known that 
pain continues to be the most feared complication during 
treatment.38–40 In 2008, the total number of new cancer 
cases, based on the International Agency for Research on 
Cancer, was 12,662,554 (52.26% men), while for 2030 ∼21 
million new cases of cancer are expected.41 Mortality is 
strongly influenced by cancer type. The overall or mortality 
numbers worldwide in 2008 were 7,564,802 (∼59.75% of 
total incidence). Among the cancer types, the best survival 
rates (mortality/incidence × 100) are for thyroid and testis 
cancer (16% and 18%, respectively), while the worst are for 
liver and pancreas cancer (93% and 96%, respectively).42 The 
very low survival rate is probably strongly influenced by the 
high mortality induced by lung cancer (which accounts for 
∼18.2% of total cancer mortalities).43
Cancer usually occurs in mature/old people, except 
osteosarcoma, which is typically diagnosed in young 
people (10–20 years old) and rarely in old people,44,45 in 
the extremity of the long bones, especially in the femur.46 
There are 45 main types of primary bone tumor, the most 
important being osteosarcoma (35.1% of the primary bone 
tumors), followed by chondrosarcoma, Ewing’s sarcoma, and 
chondroma. By sex, males are more exposed to bone cancer 
(4% incidence in males compared to 3% in females),47 even 
though osteosarcoma develops earlier in females compared 
with males (by about 2 years).46
Cancer treatment is mainly based on surgery and radio­ 
and chemotherapy, but also other unconventional therapies 
are available: hyperthermia, targeted therapy, immuno­ or 
phototherapy, the use of nanoparticles or stem cell trans­
plants, or many other less used therapies.48 Hyperthermia is 
being used more and more as complementary therapy. The 
main result of the application of this therapy is decreasing 
chemotherapeutic doses or levels of radiation needed to 
Table 1 Composition of bone and its substitutes
Bone28,29 50–74 wt% mineral phase; mainly HA 45%–58%, 
carbonate ∼4%, citrate ∼0.9%, sodium ∼0.7%, 
magnesium ∼0.5%, but also many other trace 
elements, such as Cl–, F–, K+, Sr2+, Pb2+, Zn2+, Cu2+, 
Fe2+; 16–40 wt% organic (85%–90% collagen);  
,10 wt% water
Substitutes29–35 Metals and alloys (first-generation bone grafts): 
titanium and its alloys, stainless steel, Co–Cr alloys
Ceramics and polymers (second-generation bone 
grafts): calcium phosphates, Al2O3, ZrO2; collagen, 
gelatin, chitosan, chitin, alginate, PLLA, PLGA, 
PvA, PMMA, Pe, PCL
(Nano)composite (third-acellular materials and 
fourth-generation bone grafts, containing cells  
or derived): COLL/HA, HA/gelatin, HA/chitosan,  
HA/alginate, HA/PLGA, HA/PLLA, HA/Pe,  
HA/PvA, COLL/PvA/HA
Abbreviations: COLL, collagen; HA, hydroxyapatite; PvA, polyvinyl alcohol; 
wt, weight; PLGA, polylactide-co-glycolide; PMMA, polymethyl methacrylate; PE, 
polyethylene; PCL, poly-ε-caprolactone; PLLA, poly-L-lactic acid; Co-Cr alloys, 
Cobalt-Chrom alloys.
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maintain or even improve the efficiency of the treatment.49–51 
Also, the use of nanoparticles showed a significant antitumoral 
effect, alone or in association with other therapies.52–55 These 
alternative therapies are mostly in the experimental phase of 
research, present an exciting challenge for the present, and will 
probably offer solutions for cancer treatment in the future, but 
there are also some alternative therapies currently available for 
cancer treatment, such as Doxil® (Janssen, Beerse, Belgium) 
and Abraxane® (Celgene, Summit, NJ, USA).55
Drug­delivery systems are also used for different kinds of 
cancer. The most popular drug­delivery systems are based on 
polymers and ceramics and their composites. Polymers are 
by far the most used drug­delivery systems, the most used 
being polyethylene glycol (PEG), polyethylene oxide, poly­
ε­caprolactone, chitosan, alginate, polyvinyl alcohol (PVA), 
polymethyl methacrylate, cellulose, etc.56–67 Also, proteins 
(collagen being the most abundant) are known as support 
for drug­delivery systems, but usually their high chemical 
and physical instability present technical problems related 
to synthesis and storage.68–71 PVA is extremely useful for 
chemoembolization, and in certain conditions can be loaded 
with various antitumoral drugs, such as cisplatin, doxorubi­
cin, mitomycin C, and ethiodol.67,72–74 Ceramic drug­delivery 
systems are also used for the treatment of bone cancer.75
Collagen–hydroxyapatite  
composite materials
Collagen is a special class of proteins present in many tissues 
and organs. The history of collagen starts in 1960 with the 
discovery of the first representative of this class. Currently, 
29 types of collagen76 are known. From the point of view 
of distribution and biomedical applications, type I collagen 
is by far the most abundant and used variety. The intensive 
use of type I collagen can be easily explained based on the 
following: 1) there are a large number of type I collagen 
precursors (especially bovine calf); 2) the extraction technol­
ogy is convenient (even native, fibrillar collagen is obtained 
under controlled conditions, collagen being susceptible to 
denaturation), because of the short extraction time with 
cheap reactants, especially if compared with the technology 
of extraction of type V collagen from bone.77–79 In the case 
of bone, a supplementary step is required, which consists of 
bone decalcification with hydrochloric acid and/or ethyl­
enediaminetetraacetic acid.80–82 Once extracted, the native 
or denatured collagen can be stored as gel or transformed in 
fibers or matrices.77
It is worth mentioning that type I collagen is also com­
mercially available and used as wound dressing, especially in 
the case of burns,83,84 as a main component of many creams 
designed for care or treatment of skin laxity, rhytides, or 
photoaging,85 or as a component of many engineered materi­
als used for bone regeneration and cancer treatment.70,78,86,87 
Collagen has also been used since 1980 as a drug­delivery 
system for ophthalmic agents (especially the antibiotics 
gentamicin and vancomycin),88 the trend being to extend the 
use of this material in obtaining many other drug­delivery 
systems.71,78,89
Despite intensive research efforts in the field of bone and 
bone grafts,29,90–94 the properties of the materials obtained are 
still far from those of healthy bone.95 Many types of materials 
have been separately attempted as bone grafts, such as ceram­
ics32,96,97 and polymers,98,99 or combined in different manners 
to obtain composite materials.12,22,23,27,29,93,100–108 Collagen–
hydroxyapatite (COLL/HA) composites are desired materials 
for bone grafting, especially due to their very good compo­
sitional similarity with bone,1,28 but also as drug­delivery 
systems.109–113 COLL/HA composite materials are currently 
extensively used as bone grafts.12,21,33,34,93,100–108,114–117 Obvi­
ously, the biological properties as well as the mechanical 
properties are influenced by the manufacturing process. The 
size and crystallinity of hydroxyapatite crystals are essential 
parameters that influence the biological properties,95,118 mate­
rials based on smaller crystals inducing less inflammatory 
response.95
Most studied are the porous COLL/HA composite mate­
rials, which could be considered especially for trabecular 
bone grafting and reconstruction, but can also be used for 
compact bone reconstruction. The biointegration of COLL/
HA scaffolds is strongly influenced by porosity and pore size. 
Generally, it can be assumed that 150–200 µm pores are opti­
mal for rapid osteointegration.119 Larger pores are unwanted, 
because the mechanical properties of the graft drastically 
decrease, while narrower pores limit cell penetration inside 
the graft.120,121 Porosity and pore size can be controlled by 
different parameters, such as precursor concentration, drying 
conditions, presence of different components, etc.13,22 Usually, 
COLL/HA composite materials with high porosity are 
obtained from diluted, mineralized collagen gel followed by 
freeze­drying. Control of porosity can easily be achieved 
by controlling the drying process, (eg, air­drying followed by 
freeze­drying).13 It has been proved that porosity decreases 
upon increase in air­drying time/extent.12,13 The explanation 
is very simple: air­drying is driven by capillary action that 
makes the material shrink and become denser during the 
evaporation of liquid water.12 Conversely, capillary forces 
are absent in freeze­drying, which involves sublimation of 
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frozen water, therefore maintaining the initial morphology 
of the porous structure. Based on literature data published 
by us,13 the evolution of the porosity of samples obtained by 
combined drying is presented in Table 2, and ranges between 
95% and 38%.
More compact composite materials are usually obtained 
from collagen gel by mineralization under such conditions 
that allow continuous material restructuring (Table 2, sample 
SA, COLL­PVA 1:2 A, or COLL­PVA/HA 1:2:3 A). Porosity 
can fall below even 5% if centrifugal sedimentation is used 
and only then dried in air.
Figure 1 presents the morphology of some COLL/HA 
composite materials obtained by mineralization of collagen 
in different forms (gel, matrix, or fiber).12,21,115 From collagen 
gel, both porous and compact materials as well as materials 
with intermediate porosity can be obtained. The mineraliza­
tion of collagen matrix usually leads to porous composite 
materials. Probably, under certain conditions, collagen matri­
ces and fibers can be processed to more compact materials. 
Porous composite materials have been tested as drug­delivery 
systems because, similarly with natural bone, the exchange 
rate (here the release rate) of the porous materials is higher 
than the release rate from compact materials.
Multifunctional materials
A lot of materials have been tested as delivery support 
for bone­related diseases. A short review on this specific 
topic was recently published by Soundrapandian et al.122 
Most of these drug­delivery systems are based on the 
combination of different polymers with bioglass or calcium 
phosphates. Even if natural polymers are more suitable, 
a lot of composite materials based on synthetic polymers, 
such as polycaprolactone, poly(d,l­lactide), polylactide­co­
glycolide (PLGA), or polymethyl methacrylate, have been 
also regarded with increasing interest.122–124 The enhanced sta­
bility of synthetic polymers in comparison with natural ones 
explains the higher number of composite materials based on 
synthetic polymer matrices. Further, the possibility of tailor­
ing the composition of synthetic polymers enables a broader 
range of properties to be obtained for the final composites, 
including mechanical properties, drug­release rate, etc.
Starting from the well­established materials for bone 
grafting, different kinds of natural or synthetic components 
(Table 3) have been added in order to induce some new 
functionalities. Multifunctional materials are being regarded 
with increasing interest for both industrial and biomedical 
applications.125,126 The multifunctional features of collagen 
and COLL/HA composite materials can be induced by the 
incorporation of various components, such as bone mor­
phogenic protein,127–131 vitamins,110,132 bisphosphonates,111,133 
antibiotics,69,112,113 magnetite,116 cytostatics,70 or even more 
complex systems.134 A main functionality of many of 
these systems is related to their ability to deliver the active 
component. Perhaps the most studied drug­delivery systems 
are those loaded with antibiotics or analgesics.134 For the 
treatment of severe bone defects, surgical intervention might 
be required, because otherwise self­healing would be very 
slow, or even abnormal repair could happen.29 The current 
protocols in the case of surgical intervention include the 
administration of antibiotics. A better alternate is to use bone 
grafts with antibacterial activity (for instance, an antibiotic­
loaded bone graft), because the local delivery of the antibiotic 
reduces the systemic toxicity of these drugs.135,136 The use of 
analgesic­loaded materials is a real need in the treatment of 
many diseases. In some cases, drug­loaded systems are easy 
to apply clinically. For instance, in the case of bone cancer, 
resection of the tumoral tissue is often required, leaving a 
bone defect that needs to be filled with bone­regenerative 
material. Bone fillers can in fact be more complex systems 
incorporating pharmaceutically active substances (analgesic 
and/or antitumoral drugs), allowing them to be released 
in situ.70,134 Generally, the presented multifunctional systems 
were developed in order to assist natural repair mechanisms 
(bone morphogenic protein presence improves the rate of 
bone regeneration, bisphosphonate indirectly favors bone 
formation by suppressing bone resorption) or even to act as 
Table 2 Influence of preparation route and composition on the 
porosity of different samples
Sample Porosity, % Observations
CAD 0 95 CAD samples obtained 
by controlled air-drying, 
followed by freeze-drying 
Data extracted from 
Andronescu et al13
CAD 30 94
CAD 48 93
CAD 76 92
CAD 96 88
CAD 173 54
CAD 199 38
SA 16 COLL/HA material obtained 
by self-assembly12 (data not 
presented in that manuscript)
COLL-PVA 1:2 L 93 “L” samples obtained by 
freeze-drying 
“A” samples obtained by 
air-drying 
Data extracted from Ficai et al5
COLL-PVA 1:2 A 19
COLL-PVA/HA 1:2:3 L 79
COLL-PVA/HA 1:2:3 A 14
COLL/HA centrifugation 3 COLL/HA material obtained 
by mineralization followed 
by centrifugal sedimentation 
(data not published)
Abbreviations: COLL, collagen; HA, hydroxyapatite; PvA, polyvinyl alcohol.
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drugs (for avoiding infections [antibiotics] or even to fight 
against cancer [cytostatics] or other bone­related diseases). 
All these systems can be assimilated with drug­delivery 
systems and could be used to treat diseases from simple bone 
defects/fractures up to bone cancer. It is expected that clini­
cal trials will be positive, because local administration will 
improve drug efficiency and limit side effects.70,137
Drug-delivery systems  
for bone cancer treatment
Research on cancer treatment has focused on two main 
areas: 1) developing new drugs, and 2) improving the 
activity of existing drugs by reducing their side effects. 
The main strategy for improving the activity of antitumoral 
agents is local delivery. A lot of drug­delivery systems were 
proposed and tested between 1991 and 2013,138 such as 
PLGA/doxorubicin,139 chitosan/paclitaxel,140 polyurethane/
curcumin,141 chitosan/ellagic acid,142 alginate/cisplatin,62 
poly­l­lactic acid/paclitaxel,143 PLGA/isopropyl myristate/
paclitaxel,143 PEG–poly(aspartic acid)/adriamycin,144 gela­
tin/doxorubicin,145 hydroxyapatite/platinum complexes,146,147 
or COLL/HA/cisplatin.70
Apatite­based materials are extensively used as bone filler/
grafts.148–150 This is why many drug­delivery systems designed 
for bone­disease treatment are based on hydroxyapatite. For 
instance, hydroxyapatite/cisplatin drug­delivery systems 
were obtained and tested as delivery systems of different 
platinum complexes.147,151–154 Many trials were taken into 
account, focusing on the synthesis route, drug content, 
porosity, pore size, etc. Hydroxyapatite samples with dif­
ferent porosity fractions (58%, 76%, and 82%) and average 
pore sizes (15 µm, 21 µm, and 35 µm) were obtained by the 
gel­casting method followed by cisplatin loading.147 Percent­
age cisplatin recovery after 168 hours increased from 21% 
to 28% and 42% as porosity fractions increased within the 
aforementioned range (58%–82%). Control of the release 
rate is of paramount importance, because long­term deliv­
ery could decrease cancer recurrence by reducing remnant 
cancerous cells.70
Recently, Abe et al developed new paclitaxel­loaded 
hydroxyapatite/alginate composite material for the treatment 
of metastatic spine cancer,153 which develops frequently in 
patients with breast cancer. Based on animal experiments, the 
use of paclitaxel­loaded hydroxyapatite/alginate composite 
COLL/HA composite materials
derived from collagen matrices
COLL/HA composite materials
derived from collagen matrices
COLL/HA composite materials
derived from collagen gel
COLL/HA composite materials
derived from collagen gel
Gel Matrix Fiber/s
COLL/HA
composite
materials
derived
from
collagen
fibres
100 µm100 µm
200 µm
200 µm200 µm
200 µm
200 µm
200 µm
Figure 1 Collagen (COLL) forms and their COLL/hydroxyapatite (HA) composite (nano)materials.
Notes: Reprinted from Chem Eng J.160. Ficai A, Andronescu e, voicu G, et al. Self assembled collagen/ hydroxy apatite composite materials. 794–800. Copyright (2010), with 
permission from elsevier.12 Reprinted from Mater Lett. 64. Ficai A, Andronescu E, Trandafir V, Ghitulica C, Voicu G. Collagen/hydroxyapatite composite obtained by electric 
field orientation. 541–544. Copyright (2010), with permission from Elsevier.21 Adapted from Golub LM. Special Issue: Clinical Applications of Non-Antbacterial Tetracyclines 
Introduction. Pharmacol Res. 2011;63:99–101.114
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beads led to 140%–150% increases in disease­free time as 
well as survival time compared with control animals.
Itokazu et al developed some drug­delivery  systems 
based on hydroxyapatite and cytostatics for bone 
cancer treatment.177–179 They proved that porosity and pore 
size influenced the release rate of both doxorubicin and 
methotrexate. The implantation of these ceramic blocks 
at the tumor site led to a reduction in dose of the antitu­
mor agent, and consequently the risk of systemic toxicity 
decreased drastically compared with conventional systemic 
administration. The improved contact of antitumor agents 
with tumoral cells is expected to reduce the recurrence and 
metastasis of cancer.
A gelatin/doxorubicin drug­delivery system145 was 
obtained and tested for the treatment of bone cancer, 
because doxorubicin is one of the most potent antitumor 
agents in use for bone cancer treatment, while the gela­
tin could act, after doxorubicin release, as a scaffold for 
bone regeneration. The classical administration route of 
doxorubicin is undesirable because of severe side effects. 
A general way to reduce side effects is to avoid intravenous 
administration of antitumor agents by using drug­delivery 
systems. In the case of bone cancer, the use of implantable 
gelatin/doxorubicin could be a promising way of targeted 
delivery of doxorubicin to tumoral tissue. The rate of 
delivery could be easily controlled by the degree of cross­
linking and porosity.
COLL/HA–cisplatin is a remarkable material for the 
treatment of bone cancer because it assures two functions: 
targeted delivery of cisplatin and acting as a regenerative 
scaffold.70 For this reason, samples were obtained and tested 
from the point of view of cisplatin­induced cytotoxicity. The 
delivery curve of cisplatin has two independent regions: 
a fast delivery up to 2 hours, followed by a sustained delivery 
of cisplatin up to 26 hours.70 The short release time can be 
exploited by choosing a proper polychemotherapeutic method 
that includes the cisplatin release and further traditional 
administration of complementary cytostatics.181
Bone cancer is usually associated with terrible pain.182–184 
Up to 30% of patients with recently diagnosed cancers report 
pain. With the evolution of the cancer, the pain becomes more 
intense, and about 80% of patients with primary bone cancer 
and over 90% of patients with metastases to osseous struc­
tures need ever­stronger drugs for pain management.39,185–187 
Based on the World Health Organization analysis, pain inten­
sity as well as pain management is classified at three levels. 
The lowest level of pain is usually treated with nonopioid 
and/or adjuvant drugs (aspirin and acetaminophen being 
extensively used), the middle and worst levels of pain need 
increasing doses of opioids (and also with increasing effi­
ciency from weak [codeine, for instance] to strong opioids 
[morphine, for instance]) combined or not with nonopioid 
and/or adjuvant drugs.186 In the case of severe pain, systems 
with immediate or sustained release are used.187
Magnetite and magnetite-based  
materials for bone cancer treatment
An overview of the most important applications of magnetite 
and magnetite­based materials is presented in Figure 2. Pure 
magnetite is rarely used for cancer treatment, in particular 
because of its high tendency of agglomeration and high 
reactivity. This is why many researchers have attempted to 
functionalize its surface from simple fatty acids,188 up to 
Table 3 Common components used for inducing bone graft 
multifunctionality
Component Observations References
Collagen Support material for tissue  
regeneration (especially  
skin-tissue regeneration)
83,84
Hydroxyapatite Support material for tissue  
regeneration (especially for  
bone-tissue regeneration)
95
BMPs Improve bone regeneration 127–131 
155–158
Bisphosphonate Synthetic compounds that are  
taken up preferentially by the  
skeleton and suppress osteoclast- 
mediated bone resorption
133,159
vitamins 1,25 Dihydroxycholecalciferol  
(D3) – calcium homeostasis 
vitamin K – responsible with  
bone mineralization
160 
 
109,132, 
160
Antibiotics Antibacterial purpose  
(gentamicin, norfloxacin,  
ciprofloxacin, vancomycin)
111,112, 
161
Analgesics Local analgesics are used  
especially for pain management
14
Nanoparticles 
 Magnetite 
 Silver
 
Cancer therapy by hyperthermia 
Magnetic resonance imaging 
Drug delivery and targeted  
delivery 
Antibacterial and antitumoral  
effects
 
116,162,163
164,165 
165–167 
168–172
Cytostatics Antitumoral effects 70,173–175
Glycosaminoglycans 
(hyaluronan and  
chondroitin  
sulphate)
–  modulate the attraction of skin  
and bone precursor cells and  
their subsequent differentiation  
and gene expression
–  regulate the action of proteins 
essential to bone and skin  
regeneration
176,177
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complex agents, such as aminophosphonic acid, diols and 
polyols, polyhydroxy acids, siloxanes, thioacids, etc.189 As 
presented in Figure 2, magnetite and magnetite­based mate­
rials are efficient in cancer diagnosis as well as in cancer 
 treatment, including hyperthermia as well as drug transport 
and targeted delivery. The hyperthermia is produced by 
magnetite when a proper alternating electromagnetic field 
is applied. The output power and the applied frequency are 
essential for producing medical hyperthermia, especially in 
the case of deep organs/tissues.190 Usually, these radiations 
are of low power and should induce low toxicity.191
Magnetic materials proved its effectiveness in the treat­
ment of different diseases, including cancer treatment, by 
combining surgery – as a conventional treatment and hyper­
thermia – as an alternate route of treatment. A methodology 
of treating bone cancer was presented by Andronescu et al,116 
(Figure 3) and consists of two main parts. The first step is 
assimilated with the surgical intervention of resection of 
the tumoral tissue, while the second step consists of filling 
the resulting bone defect with multifunctional materials. 
Once implanted, bone healing starts due to the presence of 
COLL/HA composite material. The magnetic nanoparticles 
can be activated, externally and at any time, by applying an 
electromagnetic field that induces hyperthermia.
Even if only a few materials are based on COLL/ 
HA–Fe
3
O
4
,116,134 perhaps, due to the high sensibility of the 
collagenous structure, their potential is great. The work 
realized by Andronescu et al116 presents the preparation of 
different COLL/HA–Fe
3
O
4
 with a 1:4 ratio of COLL:HA 
and 1%, 2%, and 5% magnetite. The in vitro studies revealed 
that mild hyperthermia is produced even at low magnetite 
content. In the case of COLL/HA–Fe
3
O
4
 with 1% magnetite, 
the maximum temperature reached was ∼41°C, which means 
mild hyperthermia, while at 5% magnetite the maximum 
temperature exceeded 45°C (Figure 4). All these data were 
obtained using thermostated samples (37°C) at 150 kHz.
The aforementioned methodology of bone cancer treat­
ment can be easily adapted for more complex material 
drug­delivery systems, such as COLL/HA–Fe
3
O
4
–cyto­
static, COLL/HA–Fe
3
O
4
–analgesic, COLL/HA–Fe
3
O
4
–Me 
(Me = Au, Ag), COLL/HA–Fe
3
O
4
–Me–cytostatic, COLL/
HA–Fe
3
O
4
–Me–analgesic, or even COLL/HA–Fe
3
O
4
–
Me–analgesic–cytostatic.134 These multifunctional materi­
als assure the convergence of conventional (surgery and 
chemotherapy) and alternative (hyperthermia, antitumoral 
effect of some metallic nanoparticles, phototherapy, and pain 
management due to the presence of analgesics) routes of 
bone cancer treatment. It is expected that due to the uncon­
ventional component of bone cancer treatment (as well as the 
targeted delivery of chemotherapeutic drugs) that the content 
of chemotherapeutic drugs will decrease and consequently 
systemic toxicity will be minimized.
For instance, Campbell et al192 synthesized quasicubic 
magnetite/silica core–shell nanoparticles that proved to 
be enhanced magnetic resonance imaging (MRI) contrast 
agents for cancer imaging. The synthesis of Fe
3
O
4
@SiO
2
 
was performed from prefabricated magnetite nanoparticles 
by controlled hydrolysis of Tetraethylorthosilicate with the 
formation of a silica network onto the magnetite nanopar­
ticles. Using these quasicubic magnetite/silica nanoparticles, 
in vitro and in vivo experiments were carried out. Based on 
the in vivo experiments on mice infected with PC3 human 
prostate cancer cells, the change in MRI signal was up to 
Magnetite
Bioseparation Drug deliveryGene delivery Drug transport
Functionalized magnetite
Modified magnetite
MRI Biosensors Cancer therapyby hyperthermia
Figure 2 Applications of magnetite and magnetite-based materials.
Abbreviation: MRI, magnetic resonance imaging.
Multifunctional
system
implantation
Multifunctional system
for bone grafting and
hyperthermia effect
Alternating
electromagnetical
field Healing
Remaining tumoral cell
Bone defect
Tumoral bone tissue
Tumoral bone excision
Figure 3 Schematic representation of bone cancer treatment by combined therapy (surgery and hyperthermia).
Note: with kind permission from Springer Science+Business Media: J Mater Sci—Mater M., Synthesis and characterization of collagen/hydroxyapatite:magnetite composite 
material for bone cancer treatment. 21, 2010, 2237–2242, Andronescu E, Ficai M, Voicu G, Ficai D, Maganu M, Ficai A, figure 2.116
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80% for 100 µg/mL Fe, a value that is significantly higher 
than reported results obtained with other materials, which 
reach up to only 15%–20%. The presence of silica led to a 
higher uptake of PC3 prostate cancer cells compared with 
pure magnetite. PC3 prostate cancer cell viability decreased 
once the content of Fe increased from 0 to 100 µg/mL.191
Treating bone cancer with magnetite and/or magnetite­
based materials has also been attempted with different 
materials, such as polymethyl methacrylate/Fe
3
O
4
,193,194 
HA/Fe
3
O
4
,195–198 glass­ and bioglass­based composites,199,200 
and complex polymer/ceramic composite materials with 
various magnetite content.116,201,202 Based on the literature 
survey, most materials designed for bone cancer treatment 
by hyperthermia are based on calcium phosphates or bioglass 
and magnetite.
Conclusion and perspectives
Cancer remains the second­most common cause of death 
in the world, despite advances in prevention and early 
detection and newer treatment protocols. The development 
of new antitumoral agents as well as the development of 
more efficient treatment strategies are current pursuits for 
scientists. Chitosan and PEG have been intensively studied 
for drug delivery in many applications, including cancer 
treatment. Only a few papers have dealt with collagen­based 
support materials, most probably because of the high chemi­
cal sensibility of this protein in comparison with chitosan, 
PEG, alginate, etc. It is expected that the use of collagen for 
the preparation of drug­delivery systems of cytostatics will 
be continued in the future. Expected applications are bone 
cancer treatment by using composite materials based on col­
lagen and calcium phosphates, skin cancer treatment by using 
collagen­based polymeric materials, or even colon cancer, 
collagen being a good carrier through the stomach.
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